You are here

AnaptysBio

Catalysts ahead for the smaller players

Catalysts ahead for the smaller players

EP Vantage

BioXcel Therapeutics

Calliditas Therapeutics

Esperion Therapeutics

Nektar Therapeutics

Oramed Pharmaceuticals

Pliant Therapeutics

Selecta Biosciences

Swedish Orphan Biovitrum

Vera Therapeutics

Viking Therapeutics

Flag link:

AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy

AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy

Fierce Biotech

hidradenitis suppurativa

Flag link:

Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials

Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials

Fierce Biotech

venture capital

autoimmune disease

Flag link:

AnaptysBio CEO Exits After Decade in the Role

AnaptysBio CEO Exits After Decade in the Role

BioSpace

Flag link:

The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties

The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties

Endpoints

Flag link:

AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure

AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure

Seeking Alpha

clinical trials

palmoplantar pustulosis

Flag link:

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

Endpoints

Flag link:

AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future

AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future

Endpoints

clinical trials

Flag link:

Here's Why AnaptysBio Rose 22.1% in May

Here's Why AnaptysBio Rose 22.1% in May

Motley Fool

Flag link:

Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

Motley Fool

Flag link:

Top 7 Companies in Biotech Beach by Revenue

Top 7 Companies in Biotech Beach by Revenue

BioSpace

Acadia Pharmaceuticals

Mirati Therapeutics

Flag link:

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Fierce Biotech

Stanford University

Flag link:

AnaptysBio shares collapse after 'worst case scenario' for key drug

AnaptysBio shares collapse after 'worst case scenario' for key drug

Biopharma Dive

clinical trials

Flag link:

AnaptysBio Prepares for a Potential Gear Shift

AnaptysBio Prepares for a Potential Gear Shift

Yahoo/Motley Fool

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Yahoo/Benzinga

Leap Therapeutics

Cidara Therapeutics

Spark Therapeutics

clinical trials

Flag link:

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Stat

monoclonal antibodies

Flag link:

AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool

AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool

Motley Fool

Flag link:

AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data

AnaptysBio plans phase 2b peanut allergy trial after taking positives from POC data

Fierce Biotech

clinical trials

Flag link:

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

Motley Fool

Flag link:

4 Biotechs Ready to Kill the Market in 2018

4 Biotechs Ready to Kill the Market in 2018

BIospace

Sangamo Therapeutics

Sino Biopharmaceutical

Flag link:

Pages